Gossamer Bio Inc (OQ:GOSS)

Business Focus: Biotechnology & Medical Research

Oct 13, 2020 07:04 am ET
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced topline results from its Phase 2b LEDA trial in patients with moderate-to-severe eosinophilic asthma and its
Oct 12, 2020 08:07 am ET
Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates
Gossamer Bio, Inc. (Nasdaq: GOSS), today announced multiple updates for its GB004 program. GB004 is an oral, gut-targeted HIF-1α stabilizer, designed to promote mucosal healing and resolve local inflammation through a non-immunosuppressive mechanism of action in patients with inflammatory bowel disease.
Oct 09, 2020 08:01 am ET
Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present data relevant to GB004 at United European Gastroenterology Virtual Week 2020, which tak
Sep 10, 2020 07:07 am ET
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation in two upcoming investor conferences. Sheila Gujrathi, M.D., Chief Executive Officer and C
Sep 07, 2020 11:00 am ET
Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the Virtual European
Aug 11, 2020 04:01 pm ET
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter 2020 and provided a corporate update.
Aug 10, 2020 08:00 am ET
Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases, ARDS associated with COVID-19, and diabetic complications, will release its financial...
Aug 05, 2020 08:31 am ET
Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present four posters with data relevant to its GB001 and GB002 programs at the American Thoraci
Jun 08, 2020 09:00 am ET
Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader...
Jun 02, 2020 09:21 am ET
GOSS FINAL DEADLINE TODAY: Rosen, a Top Ranked Law Firm, Reminds Gossamer Bio, Inc. Investors of Important June 2 Deadline in Securities Class Action – GOSS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the “IPO” or “Offering”); and/or...
Jun 01, 2020 07:35 am ET
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its participation in two upcoming investor conferences. Chief Executive Officer and Co-Founder Sheila Gujrat
May 29, 2020 12:50 pm ET
GOSS FINAL DEADLINE TUESDAY: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Reminds Gossamer Bio, Inc. Investors of Important June 2 Deadline in Securities Class Action – GOSS
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the “IPO” or “Offering”); and/or (ii) between February 8, 2019 and December 13, 2019, inclusive (the “Class Period”), of the important June 2, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Gossamer investors under the federal securities laws.
May 29, 2020 08:07 am ET
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Vir
May 27, 2020 04:30 pm ET
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Sy
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY...
May 27, 2020 04:30 pm ET
Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Sy
SAN FRANCISCO and CINCINNATI, May 27, 2020 /PRNewswire/ -- Aerpio Pharmaceuticals, Inc. ("Aerpio") (Nasdaq: ARPO) and Quantum Leap Healthcare Collaborative™ (Quantum Leap) announced today an agreement has been reached to evaluate razuprotafib in a new randomized, investigational treatment arm in the I-SPY COVID Trial for the treatment of acute respiratory distress syndrome (ARDS) in adult patients with moderate to severe COVID-19. ...
May 27, 2020 01:00 pm ET
GOSS SHAREHOLDER UPDATE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASDAQ: GOSS) (1) pursuant and/or traceable to the Company’s initial...
May 27, 2020 07:36 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 26, 2020 09:00 am ET
Notice of June 2, 2020 Lead Plaintiff Deadline for Shareholders in the Gossamer Bio, Inc. Securities Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) common stock between February 8, 2019 and December 13, 2019 (the “Class Period”), including acquirers of Gossamer stock pursuant to the Company’s February 8, 2019 initial public offering (“IPO”), have until June 2, 2020 to seek appointment as lead plaintiff in a securities class action lawsuit. The case is captioned Kuhne v. Gossamer Bio, Inc., No. 20-cv-00649 (S.D. Cal.), and is assigned to Judge Dana M. Sabraw. The Gossamer Bio securities class action lawsuit charges Gossamer, certain
May 22, 2020 04:18 pm ET
Shareholder Alert: Robbins LLP Announces Gossamer Bio, Inc. (GOSS) Sued for Misleading Shareholders
Shareholder rights law firm Robbins LLP announces that a purchaser of Gossamer Bio, Inc. (NASDAQ: GOSS) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between February 8, 2019 and December 13, 2019, as well as violations of the Securities Act of 1933 pursuant to
May 21, 2020 04:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 20, 2020 02:25 am ET
GOSSAMER DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Gossamer Bio, Inc. To Contact The Firm
NEW YORK, May 20, 2020 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Gossamer Bio, Inc. ("Gossamer" or the "Company")(NASDAQ:GOSS) of the June 2, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
May 19, 2020 01:24 am ET
Gossamer Bio Announces Pricing of Concurrent Public Offerings of Common Stock and Convertible Senior Notes due 2027
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its underwritten public offering of 9,433,963 shares of its common stock at a price to the public of $13.25 per share and the pricing of $200.0 million aggregate principal amount of its 5.00% convertible senior notes due 2027. The aggregate gross proceeds to Gossamer from the offerings, before deducting the underwriting discounts and commissions a
May 18, 2020 04:01 pm ET
Gossamer Bio Announces Proposed Concurrent Public Offerings of Common Stock and Convertible Senior Notes Due 2027
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it intends to offer, subject to market and other conditions, shares of common stock and convertible senior notes due 2027 (the “notes”) in separate concurrent underwritten public offerings registered under the Securities Act of 1933, as amended.
May 17, 2020 01:08 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 13, 2020 01:00 pm ET
GOSS & ZM INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
May 13, 2020 08:58 am ET
FAST-APPROACHING DEADLINE: Block & Leviton Filed the First Lawsuit Against Gossamer Bio, Inc. for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, reminds shareholders that it filed the first class action lawsuit on behalf of shareholders against Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers and...
May 12, 2020 04:30 pm ET
Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924)
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced a restructuring of their licensing deal with...
May 12, 2020 04:01 pm ET
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the first quarter 2020 and provided a corporate update.
May 10, 2020 11:15 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
May 08, 2020 07:37 am ET
Gossamer Bio to Announce First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 12, 2020
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2020 financial results on Tuesday, May 12, 2020.
May 05, 2020 04:35 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 29, 2020 07:02 pm ET
Shareholder Alert: Robbins LLP Reminds Investors It Is Investigating Gossamer Bio, Inc. (GOSS) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP reminds investors it is investigating Gossamer Bio, Inc. (NYSE: GOSS) for potential violations of federal securities laws and breaches of fiduciary duty by its board members and executive officers. In its initial public offering, Gossamer offered approximately 19.8 million shares at $1
Apr 28, 2020 12:00 pm ET
GOSS & TUFN INVESTOR NOTIFICATION: Bronstein, Gewirtz & Grossman LLC Updates Investors of Class Actions and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Apr 28, 2020 10:05 am ET
LOOMING DEADLINE: Block & Leviton Filed the First Lawsuit Against Gossamer Bio, Inc. for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, reminds shareholders that it filed the first class action lawsuit on behalf of shareholders against Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers and...
Apr 28, 2020 09:00 am ET
Notice of Lead Plaintiff Deadline for Shareholders in the Gossamer Bio, Inc. Securities Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that a securities class action lawsuit has been filed in the Southern District of California on behalf of purchasers of Gossamer Bio, Inc. (NASDAQ:GOSS) common stock between February 8, 2019 and December 13, 2019 (the “Class Period”) and/or those who acquired Gossamer stock pursuant or traceable to the Company’s February 8, 2019 initial public offering (“IPO”). The case is captioned Kuhne v. Gossamer Bio, Inc., No. 20-cv-00649, and is assigned to Judge Dana M. Sabraw. The Gossamer Bio securities class action lawsuit charges Gossamer, cer
Apr 27, 2020 03:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 23, 2020 10:00 am ET
GOSS INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company’s initial...
Apr 23, 2020 12:45 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 22, 2020 10:50 am ET
The Gross Law Firm Announces Class Actions on Behalf of Shareholders of INO, XP and GOSS
NEW YORK, NY / ACCESSWIRE / April 22, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.
Apr 17, 2020 12:02 pm ET
Zhang Investor Law Announces Securities Class Action Lawsuit Against Gossamer Bio, Inc. – GOSS
Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of   Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the “IPO” or...
Apr 16, 2020 08:37 am ET
UPCOMING DEADLINE: Block & Leviton Filed the First Lawsuit Against Gossamer Bio for Securities Fraud; Shareholders Who Have Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, reminds shareholders that it filed the first class action lawsuit on behalf of shareholders against Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers and...
Apr 13, 2020 12:50 pm ET
GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASDAQ: GOSS) (1) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 12, 2020 02:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
NEW YORK, April 12, 2020 /CNW/ -- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Apr 12, 2020 02:31 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. - GOSS
NEW YORK, April 12, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980....
Apr 08, 2020 02:46 pm ET
Shareholder Alert: Robbins LLP Announces It Is Investigating Gossamer Bio, Inc. (GOSS) on Behalf of Shareholders
Shareholder rights law firm Robbins LLP informs shareholders it is investigating Gossamer Bio, Inc. (NASDAQ: GOSS) for potential violations of federal securities laws and breaches of fiduciary duty by its board members and executive officers. In its initial public offering, Gossamer offered approximately 19.8 million shares at $19.00
Apr 07, 2020 04:00 pm ET
GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company’s initial public...
Apr 07, 2020 10:00 am ET
GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:
Apr 07, 2020 09:10 am ET
Gossamer (GOSS) Class Action Alert: Johnson Fistel Encourages Investors to Contact Firm
SAN DIEGO, April 7, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of shareholders of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). The class action is on behalf of shareholders who purchased Gossamer common stock pursuant or traceable to the February 2019 initial public stock offering (the "IPO") or between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). If you wish to serve as lead plaintiff in this class action, you must move the Court no later than June 2, 2020....
Apr 06, 2020 04:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Apr 06, 2020 03:49 pm ET
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Gossamer Bio, Inc. (GOSS)
Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) in the United States District Court for the Southern District of California on behalf of those...
Apr 06, 2020 03:39 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ:
Apr 06, 2020 02:30 pm ET
GOSS INVESTOR UPDATE: Bronstein, Gewirtz & Grossman, LLC Notifies Gossamer Bio, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
NEW YORK, April 6, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer " or "the Company") (NASADQ: GOSS) (1) pursuant and/or traceable to the Company's initial public offering in February 2019 (the "IPO" or "Offering"); and/or (2) between February 8, 2019 and December 13, 2019, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/goss.     ...
Apr 03, 2020 05:32 pm ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ:
Apr 03, 2020 04:12 pm ET
EQUITY ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Announces Filing of Securities Class Action Lawsuit Against Gossamer Bio, Inc. – GOSS
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Gossamer Bio, Inc. (NASDAQ: GOSS) (i) pursuant and/or traceable to the Company’s initial public offering in February 2019 (the “IPO” or “Offering”); and/or (ii) between February 8, 2019 and December 13, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Gossamer investors under the federal securities laws.
Apr 03, 2020 02:45 pm ET
UPDATE: Block & Leviton Announces that it Has Filed a Lawsuit Against Gossamer Bio, Inc. for Securities Law Violations; Shareholders Who Have Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has filed a class action lawsuit on behalf of shareholders against Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers and directors for...
Mar 27, 2020 08:06 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gossamer Bio, Inc. – GOSS
Pomerantz LLP is investigating claims on behalf of investors Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The...
Mar 25, 2020 09:20 am ET
Gossamer Bio Investigated by Block & Leviton; Investors Who Have Lost Money Should Contact the Firm
Block & Leviton LLP (www.blockesq.com), a national securities litigation firm, announces that it has opened an investigation into Gossamer Bio, Inc. (Nasdaq: GOSS) and certain of its officers for potential securities fraud.  Investors who have lost...
Mar 24, 2020 07:00 am ET
Gossamer Bio Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the fourth quarter and year ended December 31, 2019 and provided a business update.
Mar 16, 2020 08:00 am ET
Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today reported financial results for the fourth quarter and...
Feb 18, 2020 07:00 am ET
Gossamer Bio Announces Participation in 9th Annual SVB Leerink Global Healthcare Conference
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25 at 9:30 a.m. ET.
Feb 13, 2020 07:00 am ET
Gossamer Bio Announces Data Presentations at the Congress of the European Crohn’s and Colitis Organisation
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will present two posters with data on its GB004 program at the 15th Annual Congress of th
Jan 23, 2020 07:00 am ET
Gossamer Bio Announces Data Presentation at the 2020 Crohn’s & Colitis Congress
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that data from the Company’s Phase 1 multiple ascending dose study of GB004 in healthy volunteers have been
Nov 26, 2019 07:00 am ET
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that members of the management team will participate in the following investor conferences:
Nov 14, 2019 07:00 am ET
Gossamer Bio Announces Participation in the Guggenheim Healthcare Talks Neuro/Immunology Day
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Guggenheim He
Nov 12, 2019 04:05 pm ET
Gossamer Bio Announces Third Quarter 2019 Financial Results
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the quarter ended September 30, 2019 and provided a corporate update.
Nov 12, 2019 07:00 am ET
Gossamer Bio Announces Clinical Trial Collaboration Agreement With Merck to Evaluate GB1275 in Combination With KEYTRUDA® (Pembrolizumab) in Selected Advanced Solid Tumors
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company, today announced that it has entered into a clinical collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate the combination of Gossamer’s investigational product candidate GB1275, the first-in-class oral modulator of CD11b, and Merck’s anti-PD-1 the
Nov 11, 2019 07:00 am ET
Gossamer Bio Announces Data Presentations at the American Heart Association Scientific Sessions 2019
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB002, the Company’s inhaled PDGFR inhibitor for the treatment of pulmonary arterial hyperten
Nov 08, 2019 07:00 am ET
Gossamer Bio Announces Data Presentations at the American College of Allergy, Asthma and Immunology Annual Scientific Meeting 2019
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that two abstracts supporting GB001, the Company’s oral DP2 antagonist for the treatment of asthma and allergic disease, ha
Nov 07, 2019 07:00 am ET
Gossamer Bio Announces Presentation at the Society for Immunotherapy of Cancer 34th Annual Meeting
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that GB1275, the Company’s oral CD11b modulator for oncology indications, will be featured in a trial-in-progress poster at
Nov 05, 2019 07:00 am ET
Gossamer Bio to Announce Third Quarter 2019 Financial Results and Host Conference Call and Webcast on November 12, 2019
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its third quarter 2019 financial results on Tuesday, November 12, 2019.
Sep 25, 2019 07:00 am ET
Gossamer Bio Announces Participation in the 2019 Cantor Global Healthcare Conference
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the 2019 Cantor Global Healthcare Confe
Sep 13, 2019 07:00 am ET
 Gossamer Bio Announces the Departure of Dr. Otello Stampacchia from its Board of Directors
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced Otello Stampacchia, Ph.D., of Omega Funds, resigned from the company’s Board of Directors. Dr. Stampacchia has served as a
Aug 08, 2019 04:05 pm ET
Gossamer Bio Announces Second Quarter 2019 Financial Results
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the quarter ended June 30, 2019 and provided a corporate update.
Aug 05, 2019 07:00 am ET
Gossamer Bio to Announce Second Quarter 2019 Financial Results and Host Conference Call and Webcast on August 8, 2019
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its second quarter 2019 financial results on Thursday, August 8, 2019.
May 14, 2019 06:00 am ET
Gossamer Bio Announces First Quarter 2019 Financial Results
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the quarter ended March 31, 2019 and provided a corporate up
May 09, 2019 07:00 am ET
Gossamer Bio to Announce First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 14, 2019
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its first quarter 2019 financial results on Tuesday, May 14, 2019.
May 02, 2019 07:00 am ET
Gossamer Bio Secures Debt Facility for up to $150 Million
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced it entered into a five-year senior debt facility led by MidCap Financial (MidCap).
May 01, 2019 07:00 am ET
Gossamer Bio Announces Participation in Bank of America Merrill Lynch Health Care Conference 2019
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will participate in a fireside chat at the Bank of America Merrill Lynch Health Care Conference on Tuesday, May 14 at 1:00 p.m. PT.
Mar 22, 2019 04:05 pm ET
Gossamer Bio Announces 2018 Annual Financial Results
Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the year ended December 31, 2018 and provided an update on re
Feb 22, 2019 07:00 am ET
Gossamer Bio Announces Participation in Upcoming Investor Conferences
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that Sheila Gujrathi, M.D., Chief Executive Officer and Co-Founder, will present at the following upcoming investor conferences:
Feb 12, 2019 04:05 pm ET
Gossamer Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the closing of its previously announced initial public offering of 19,837,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,587,500 additional shares, at a price to the public of $16.00 per share. Including the option exercise, the aggregate gross
Feb 07, 2019 06:17 pm ET
Gossamer Bio Announces Pricing of Initial Public Offering
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the pricing of its initial public offering of 17,250,000 shares of common stock at a public offering price of $16.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on February 8, 2019 under the ticker symbol “GOSS.” All of the shares are being offered by Gossamer Bio.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.